A novel mutation in Daniele Ammeti, Antonio Marzollo, Maria Gabelli, Melania Eva Zanchetta, Caterina Tretti‐Parenzan, Roberta Bottega, Valeria Capaci, Alessandra Biffi, Anna Savoia, Silvia Bresolin, Michela Faleschini
MECOM affects MPL regulation in vitro and results in thrombocytopenia and bone marrow failure
MECOM‐associated syndrome (MECOM‐AS) is a rare disease characterized by amegakaryocytic thrombocytopenia, progressive bone marrow failure, pancytopenia and radioulnar synostosis with high penetrance. The clinical phenotype may also include finger malformations, cardiac and renal alterations, hearing loss, B‐cell deficiency and predisposition to infections. The syndrome, usually diagnosed in the neonatal period because of severe thrombocytopenia, is caused by mutations in the MECOM gene, encoding for the transcription factor EVI1. The mechanism linking the alteration of EVI1 function and thrombocytopenia is poorly understood. In a paediatric patient affected by severe thrombocytopenia, we identified a novel variant of the MECOM gene (p.P634L), whose effect was tested on pAP‐1 enhancer element and promoters of targeted genes showing that the mutation impairs the repressive activity of the transcription factor. Moreover, we demonstrated that EVI1 controls the transcriptional regulation of MPL, a gene whose mutations are responsible for congenital amegakaryocytic thrombocytopenia (CAMT), potentially explaining the partial overlap between MECOM‐AS and CAMT.